
Dr. Ross Houston, Chief Scientific Officer, Benchmark Genetics.
Photo: Benchmark Genetics.
Leading genetics, nutrition and aquaculture health company Benchmark Genetics has announced the appointment of Dr. Ross Houston as its new Chief Scientific Officer (CSO), at what it describes as a "pivotal time" for the firm, which recently became an independent company as part of Novo Holdings investment portfolio.
"In this new role, Ross will lead our global research and development, oversee breeding programmes and product design, and drive strategic initiatives to strengthen our position as a global leader in applied aquaculture genetics," the company stated in a news announcement.
Houston joined Benchmark in 2022 as the company's Director of Innovation and Genetics, having previously held the role of Chair of Aquaculture Genetics at the prestigious Roslin Institute in Edinburgh.
He is considered a leading aquaculture geneticist, having published almost 150 peer-reviewed publications and being the author of several patents. During his time at Benchmark, Houston is credited with having established its Reproductive Technologies team as well as the company's molecular genetics laboratory.
“I’m honoured to take up this new leadership position at a very exciting time in Benchmark Genetics’ journey," Houston said in a press release.
"The power and value of innovation in genetics technologies to sustainable seafood production is clear, and I will focus on unlocking this potential by translating the latest science into commercial practice," he added.
His new role will see Houston report to newly-appointed CEO Dr. Geir Olav Melingen, as well as serving on the Benchmark Genetics Board.